Abdominal aortic aneurysm (AAA) is a ballooning of the aorta, the largest blood vessel in the human body, which extends into the abdomen. If the wall of this blood vessel becomes weakened, it can stretch, "balloon" out and rupture. A rupture, if left untreated, can lead to life-threatening internal bleeding. The exact cause of this condition is unknown. However, it often occurs in older adults, especially males, those with a high cholesterol level, and in smokers. There also tends to be a genetic link to this disorder.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink System for endovascular repair of abdominal aortic aneurysm (AAA) using an anatomical fixation technique with a suprarenal aortic extension.
W. L. Gore & Associates (Gore) today announced the first clinical uses of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).
Actress, writer and aortic health advocate Amy Yasbeck has joined with The University of Texas Health Science Center at Houston (UTHealth) to establish the John Ritter Research Program in Aortic and Vascular Diseases (JRRP) to combat the devastating disease that took the life of her husband, legendary comic actor John Ritter.
Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair, announced the completion of a $15 million Series AA financing. U.S. Venture Partners and Longitude Capital led the round in continuation of their commitment to Aptus' innovative technologies for the treatment of aortic aneurysms.
Research from the Society for Vascular Surgery in collaboration with the Mount Sinai School of Medicine Department of Health Evidence and Policy in New York City evaluated the data of 3.1 million patients who were at risk for an abdominal aortic aneurysm (AAA).
Aptus Endosystems Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced that several patients with aortic aneurysm disease have been successfully treated with the Aptus EndoStapling System in Europe. The innovative helical staple technology enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The company continues to build on its U.S. clinical experience which includes 176 patients and deployment of more than 900 EndoStaples.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010.
TCT 2010 will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.
Anti-abortion activists have "scored a victory" after a decision last week by the Obama administration to not allow the new high-risk pools in America to cover most abortions, The Associated Press reports.
Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases. The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD), and pulmonary embolism, independent of other known risk factors.
Ethicon, Inc., a worldwide leader in surgical care, announced today the introduction of ETHICON™ OMNEX™ Surgical Sealant, ETHICON™ Biosurgery's first synthetic sealant designed to achieve adjunctive hemostasis (stoppage of bleeding) in vascular reconstructions by mechanically sealing areas of leakage. The US Food and Drug Administration (FDA) recently granted approval of the Premarket Approval Application (PMA) for ETHICON™ OMNEX™ Surgical Sealant.
The vascular surgeons at Massachusetts General Hospital (MGH) in Boston have traditionally repaired thoracoabdominal aortic aneurysms (TAA) with a clamp and sew (CS) technique that includes neuro-protective adjuncts like epidural cooling and aggressive intercostal reconstruction (IC) to prevent spinal cord ischemia.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.
A regional quality improvement effort aimed at increasing the use of preoperative beta-blocker usage to help prevent postoperative myocardial infarction was revealed today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.
Preoperative statin therapy has a protective effect on patients undergoing elective abdominal aortic aneurysm repair that reduces risk and subsequent total hospital costs according to a new study from researchers at the East Carolina Heart Institute in Greenville, North Carolina.
Abdominal aortic aneurysms have been considered mainly a man's problem. Men, more often than women, develop a weakened and bulging area in the aorta, the body's largest artery, which poses a risk of rupture. But according to the May issue of Mayo Clinic Women's HealthSource, women aren't risk free.
The DNA Medicine Institute announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Eugene Y. Chan, M.D. titled "Optomagnetic Finger Scanner for Malaria."
According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.